Juggling the cost of quality control (QC) resources versus the risk of testing error is a balancing act no clinical laboratory manager enjoys. It is an inexact process, itself prone to error, which can impact the operations of hospital labs and independent clinical testing companies. In the current resource-constrained healthcare environment, there is pressure to improve the cost effectiveness of…
Using a new technology developed at MIT, diagnosing lung cancer could become as easy as inhaling nanoparticle sensors and then taking a urine test that reveals whether a tumor is present.
AutoLumo A1860/A1800 is the new generation of Autobio AutoLumo Series with compact structure and innovative design, providing simpler, smarter and better user experience for small and medium size labs.
Hamamatsu Photonics announces the release of a new high-speed kinetic plate imager, the FDSS-GX, designed for kinetic cell-based assay development.
Eunsin Bae, M.D. specializes in laboratory medicine and leads the Institute of Clinical Research at Seegene Inc. Her research focuses on microbiology, molecular biology, and hematology. Dr. Bae is currently working toward implementing a global clinical study and establishing an international network of clinical investigations.
The speedy, high-tech method of inexpensive, accurate and high-throughput protein biomarker assay testing is being touted as a much-needed development in point-of-care (PoC) testing.
Medical equipment that can be manufactured at low cost, is simple to use and can be easily maintained will help extend surgery to the 5 billion people worldwide who currently cannot get access to it.
In a new study, scientists from the Hematology Department, University Hospital of Clermont-Ferrand, have successfully evaluated the analytical performance of the Yumizen G DDi 2 hemostatic immunoassay.
Accurate home testing could be used for a wider range of illnesses, as new research shows the capability of smartphone-powered tests for Dengue Fever.
The advantages and limitations of the value of traceability chains in therapeutic drug monitoring will be explored during a key session at the EuroMedLab event.
Hyaluronic Acid LT Assay is an in vitro diagnostic test (IVD) for the quantitative determination of hyaluronic acid based on the latex agglutination method. This turbidimetric method can be applied to general clinical chemistry analyzers.
Autokit CH50 Assay is an in vitro diagnostic (IVD) test for the quantitative determination of total complement activity in human serum. The complement system is a part of the immune system that enhances/complements the ability of antibodies and phagocytic cells to clear pathogens from an organism.
Non-Esterified Fatty Acids (NEFA) are one of the most important metabolites and energy source of peripheral tissues. The amount of NEFA in serum decreases by physical exercise and increases by starvation, cold or smoking. An increase or decrease is also observed in diabetes, hepatic, or endocrine diseases.
Researchers have developed a diagnostic for SARS-CoV-2 that is capable of differentiating between COVID-19 and the garden-variety bug with fast turnaround.
A new study from the University of Helsinki shows that cells that are freshly isolated from lung cancers can be used to create robust drug response data. This approach can identify actionable or non-responsive treatments, illustrated by a case study in which the assay was used to guide the compassionate treatment of a patient.
The Lausanne University Hospital (CHUV) and EPFL teamed up to develop a new test that’s sensitive enough to measure the amount of SARS-CoV-2 neutralizing antibodies present in the bloodstream. The scientists’ discovery, published in Science Translational Medicine, opens promising new avenues for tracking immunity acquired by infection or vaccination.
Beckman Coulter announced the launch of an AMH test that uses a validated cut-off to aid in the assessment of poor ovarian response. This new assay helps clinicians predict poor ovarian response in those who plan to undergo controlled ovarian stimulation as part of an in vitro fertilisation (IVF) protocol.
Clinical diagnostics company Beckman Coulter launched its Access SARS-CoV-2 IgG II assay in countries accepting the CE Mark. The new Access SARS-CoV-2 IgG II assay quantitatively measures a patient’s level of antibodies in response to a previous SARS-CoV-2 infection. The ability to establish a quantitative baseline to evaluate an individual’s immune response to the SARS-CoV-2 virus allows…
The new generation troponin I assay unveiled by Beckman Coulter is helping improve heart attack diagnosis. Delivering high sensitivity, and rapid result turnaround times, every element of the Access hsTnI assay has been redeveloped and updated, including the antibodies and the paramagnetic particles used. As specialists in developing and manufacturing products that simplify and automate complex…
